Unibest
← Back to patent-cliff list

CAS 2044680-95-5

(1S,5S,6S,8S,11S,12aS)-1-[(Benzyloxy)methoxy]-6,8-dihydroxy-9,12a,13,13-tetramethyl-11-[(triethylsilyl)oxy]-1,2,3,5,6,7,8,11,12,12a-decahydro-6,10-methanobenzo[10]annulen-5-yl benzoate

Codes: (XXII)101438-60-b

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
PaclitaxelTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.